(Q34201647)

31 July 2017

1 reference

title

Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study (English)

1 reference

31 July 2017

0 references

chronic schizophrenia

1 reference

M J Cuesta

1

1 reference

31 July 2017

V Peralta

series ordinal

2

1 reference

31 July 2017

A Zarzuela

series ordinal

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

31 July 2017

Schizophrenia Research

1 reference

31 July 2017

48

1 reference

31 July 2017

1

1 reference

31 July 2017

17-28

1 reference

Neurocognitive impairment in schizophrenia and how it affects treatment options

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Comparative Doses and Costs of Antipsychotic Medication

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Pharmacologic strategies for augmenting cognitive performance in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Relationships between changes in symptom ratings, neurophysiological test performance and quality of life in schizophrenic patients treated with clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

What are the functional consequences of neurocognitive deficits in schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Risperidone versus haloperidol on secondary memory: can newer medications aid learning?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

The effect of neuroleptics on cognitive and psychomotor function

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

The effects of neuroleptics on neuropsychological test results of schizophrenics.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Are there more than two syndromes in schizophrenia? A critique of the positive-negative dichotomy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

The cognitive efficacy of atypical antipsychotics in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Data analytic techniques for treatment outcome studies with pretest/posttest measurements: an extensive primer

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

The effect of risperidone on cognition in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Studies of interference in serial verbal reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

The functional significance of symptomatology and cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

A Standardized Memory Scale for Clinical Use

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900112-2

7 January 2021

10.1016/S0920-9964(00)00112-2

Identifiers

DOI

1 reference

31 July 2017

1 reference